Jiangsu Hengrui Pharmaceuticals Co. signed a strategic licensing agreement with Bristol-Myers Squibb Co. that could be worth up to $15.2 billion, giving the U.S. drugmaker access to 13 of Hengrui’s early-stage assets and significantly boosting the Chinese firm’s global standing.
"The agreement will accelerate the development of innovative drugs and benefit patients worldwide," Hengrui Medicine said in a company announcement detailing the global strategic cooperation.
Under the terms, Bristol-Myers Squibb will pay Hengrui a total of up to $950 million in near-term payments, which includes a $600 million upfront payment, a $175 million first-anniversary payment, and a second conditional anniversary payment of $175 million in 2028. Hengrui is also eligible for further milestone payments and tiered royalties on net sales outside of mainland China, Hong Kong, and Macau.
The deal provides a substantial source of non-dilutive funding for Hengrui and serves as a major validation of its research and development platform. For Bristol-Myers Squibb, it represents a significant expansion of its early-stage pipeline in the key therapeutic areas of oncology, hematology, and immunology.
This partnership is one of the largest of its kind and highlights a growing trend of Western pharmaceutical giants turning to Chinese biotechs for innovative drug candidates. The move follows a similar pattern seen in other recent collaborations, such as GSK's recent deal with Sino Biopharmaceutical to commercialize its hepatitis B drug, bepirovisen, in China, a market that represents a third of the global disease burden for that illness.
These agreements underscore the increasing role of Chinese pharmaceutical companies in global drug development, transitioning from primarily serving their domestic market to becoming a source of innovation for multinational corporations. The significant upfront capital and potential milestone payments can accelerate research and development for firms like Hengrui, while partners like Bristol-Myers Squibb gain access to promising assets to refresh their pipelines. The deal is subject to customary closing conditions and regulatory approvals.
This article is for informational purposes only and does not constitute investment advice.
